



(11) **EP 1 765 848 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07J 73/00 ^(2006.01)

(86) International application number:
PCT/EP2005/007190

(48) Corrigendum issued on:
15.04.2009 Bulletin 2009/16

(87) International publication number:
WO 2006/002966 (12.01.2006 Gazette 2006/02)

(45) Date of publication and mention
of the grant of the patent:
21.01.2009 Bulletin 2009/04

(21) Application number: **05759142.2**

(22) Date of filing: **04.07.2005**

(54) **PROCESS FOR THE PREPARATION OF 4-AZASTEROIDS**

VERFAHREN ZUR HERSTELLUNG VON 4-AZASTEROIDEN

PROCÉDÉ POUR LA PRÉPARATION DE 4-AZASTÉROIDES

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**
Designated Extension States:
HR YU

(30) Priority: **05.07.2004 EP 04015746**

(43) Date of publication of application:
28.03.2007 Bulletin 2007/13

(73) Proprietor: **Lonza AG**
4052 Basel (CH)

(72) Inventors:
• **BESSARD, Yves**
CH-3960 Sierre (CH)
• **KUO, David**
Short Hills, NJ 07078 (US)

(56) References cited:
WO-A-95/12398

- **RASMUSSEN G H ET AL: "AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC 5ALPHA-REDUCTASE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 27, no. 12, 1 December 1984 (1984-12-01), pages 1690-1701, XP002043194 ISSN: 0022-2623**
- **RASMUSSEN G H ET AL: "AZASTEROIDS: STRUCTURE-ACTIVITY RELATIONSHIPS FOR INHIBITION OF 5ALPHA-REDUCTASE AND OF ANDROGEN RECEPTOR BINDING" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 29, no. 11, 1 November 1986 (1986-11-01), pages 2298-2315, XP000568779 ISSN: 0022-2623**
- **BRATOEFF E ET AL: "STEROIDAL ANTIANDROGENS AND 5ALPHA-REDUCTASE INHIBITORS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 12, December 1999 (1999-12), pages 1107-1123, XP000874719 ISSN: 0929-8673**
- **ISHIBASHI, K. ET AL.: "Synthesis and testosterone 5 alpha-reductase inhibitory activity of 11-substituted 4-aza-5alpha-androstane compounds" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, 1996, XP002306058**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 765 848 B8